Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene - A phase I/II clinical protocol

Journal of Neuro-Oncology

Volumn 64, Issue 1, 2003, Pages 147-154

  Ren, H ^a   Boulikas, T ^b   Soling A ^c   Warnke, P C ^a   Rainov, Nikolai G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Regulon Inc   (United States)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Glioblastoma; Interleukin 12; Intra tumoral infusion; Semliki forest virus

Indexed keywords

ANTINEOPLASTIC AGENT; CATION; DEXAMETHASONE; INTERLEUKIN 12; LIPOSOME; VIRUS VECTOR;

ADULT; ALPHAVIRUS VECTOR; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; DNA MODIFICATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOXICITY; EXTRACELLULAR SPACE; FEMALE; FOLLOW UP; GENE; GENE THERAPY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOGENETICS; KIDNEY CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MITOSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PROSTATE CANCER; RECURRENT CANCER; SEMLIKI FOREST ALPHAVIRUS; TUMOR CELL; TUMOR VOLUME; VIRUS REPLICATION;

EID: 0042063604     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024979103780     Document Type: Conference Paper

References (32)

1. Black PM: Surgery for cerebral gliomas: Past, present, and future. Clin Neurosurg 47: 21-45, 2000
2. Salford LG, Brun A, Nirfalk S: Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 69: 506-509, 1988
3. Shapiro WR: Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13: 38-45, 1986
4. Ammirati M, Galicich JH, Arbit E, Liao Y: Reoperation in the treatment of recurrent intracranial malignant gliomas, Neurosurgery 21: 607-614, 1987
5. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, Brada M: Survival in patients with recurrent gliomas as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapy. Eur J Cancer 12: 1809-1815, 1994
6. Mach N, Dranoff G: Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 12: 571-575, 2000
7. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, Rajendiran S, Tamura M, Cohen JB, Gliorioso JC: Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2: 114-120, 2000
8. Mackensen A, Lindemann A, Mertelsmann R: Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine Growth Factor Rev 8: 119-128, 1997
9. Qian HN, Liu GZ, Cao SJ, Feng J, Ye X: Experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer 12: 80-85, 2002
10. Boulikas T: Status of gene therapy in 1997: Molecular mechanisms, disease targets, and clinical applications. Gene Ther Mol Biol 1: 1-172, 1998
11. Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH: IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108: 51-62, 2001
12. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168, 2002
13. Liu Y, Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villareal LP, Black KL, Yu JS: In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 9: 9-15, 2002
14. Trinchieri G, Scott P: Interleukin-12: Basic principles and clinical applications. Curr Top Microbiol Immunol 238: 57-78, 1999
15. Asselin-Paturel C, Lassau N, Guinebretiere JM, Zhang J, Gay F, Bex F, Hallez S, Leclere J, Peronneau P, Mami-Chouaib F, Chouaib S: Transfer of the murine interleukin-12 gene in vivo by a Semliki forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 6: 606-615, 1999
16. Wolf SF, Lee K, Swiniarski H, O'Toole M, Sturmhoefel K: Cytokines and cancer immunotherapy. Immunol Invest 29: 143-146, 2000
17. Hiscox S, Jiang WG: Regulation of endothelial CD44 expression and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor. Biochem Biophys Res Commun 233: 1-5, 1997
18. Salgaller ML, Lodge PA: Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 68: 122-138, 1998
19. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2: 293-299, 2001
20. Yamanaka R, Zullo SA, Tanaka R, et al.: Induction of a therapic antitumor immunological response by intratumoral injection of genetically engineered Semliki forest virus to produce IL-12. Neurosurg Focus 9: 1-6, 2000
21. Lundstrom K, Schweitzer C, Richards JG, Ehrengruber MU, Jenck F, Mühlhardt C: Semliki forest virus vectors for in vitro and in vivo applications. Gene Ther Mol Biol 4: 23-31, 1999
22. Lundstrom K: Novel developments for applications of alphavirus vectors in gene therapy. Gene Ther Mol Biol 6: 25-31, 2001
23. Lundstrom K: Alphavirus vectors: Applications for DNA vaccine production and gene expression. Intervirology 43: 247-257, 2000
24. Hardy PA, Mazzini MJ, Schweitzer C, Lundstrom K, Glode LM: Recombinant Semliki forest virus infects and kills human prostate cancer cell lines and prostatic duct epithelial cells ex vivo. Int J Mol Med 5: 241-245, 2000
25. Murphy A-M, Morris-Downes MM, Sheahan BJ, Atkins GJ: Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki forest virus recombinant particles. Gene Ther 7: 1477-1482, 2000
26. Lundstrom K, Richards JG, Pink JR, Jenck F: Efficient in vivo expression of a reporter gene in rat brain after injection of recombinant replication-deficient Semliki forest virus. Gene Ther Mol Biol 3: 15-23, 1999
27. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG: Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 94: 474-481, 2001
28. Colmenero P, Liljeström P, Jondal M: Induction of P185 tumor immunity by recombinant Semliki forest virus expressing the P1A gene. Gene Ther 6: 1728-1733, 1999
29. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP: Cancer therapy using a self-replicating RNA vaccine. Nat Med 5: 823-827, 1999
30. Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J: Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16E6 and E7. Gene Ther 7: 1859-1866, 2000
31. Atkins GJ, Sheahan BJ, Liljestrom P: Manipulation of the Semliki forest virus genome and its potential for vaccine construction. Mol Biotechnol 5: 33-38, 1996
32. Martin F, Boulikas T: The challenge of liposomes in gene therapy. Gene Ther Mol Biol 1: 173-214, 1998